An Inhibitory Fragment Derived from Protein Kinase Cepsilon Prevents Enhancement of Nerve Growth Factor Responses by Ethanol and Phorbol Esters*

(Received for publication, June 17, 1996, and in revised form, February 21, 1997)

Bhupinder Hundle Dagger §, Thomas McMahon Dagger §, Jahan Dadgar Dagger , Che-Hong Chen , Daria Mochly-Rosen § and Robert O. Messing Dagger par

From the Dagger  Department of Neurology and Ernest Gallo Clinic and Research Center, University of California, San Francisco, California 94110 and the  Department of Molecular Pharmacology, Stanford University School of Medicine, Stanford, California 94305-5332

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES


ABSTRACT

We have studied nerve growth factor (NGF)-induced differentiation of PC12 cells to identify PKC isozymes important for neuronal differentiation. Previous work showed that tumor-promoting phorbol esters and ethanol enhance NGF-induced mitogen-activated protein (MAP) kinase activation and neurite outgrowth by a PKC-dependent mechanism. Ethanol also increases expression of PKCdelta and PKCepsilon , suggesting that one these isozymes regulates responses to NGF. To examine this possibility, we established PC12 cell lines that express a fragment encoding the first variable domain of PKCepsilon (amino acids 2-144), which acts as an isozyme-specific inhibitor of PKCepsilon in cardiac myocytes. Phorbol ester-stimulated translocation of PKCepsilon was markedly reduced in these PC12 cell lines. In addition, phorbol ester and ethanol did not enhance NGF-induced MAP kinase activation or neurite outgrowth in these cells. In contrast, phorbol ester and ethanol increased neurite outgrowth and MAP kinase phosphorylation in cells expressing a fragment derived from the first variable domain of PKCdelta . These results demonstrate that PKCepsilon mediates enhancement of NGF-induced signaling and neurite outgrowth by phorbol esters and ethanol in PC12 cells.


INTRODUCTION

Protein kinase C (PKC)1 is a multigene family of phospholipid-dependent, serine-threonine kinases that plays a central role in cell growth and differentiation. Molecular cloning studies have identified 10 isozymes encoded by 9 different mRNAs (1, 2). Based on sequence homology and biochemical properties, the PKC gene family has been divided into three groups: "conventional" PKCs (alpha , beta I, beta II, and gamma ) regulated by calcium and diacylglycerols or phorbol esters; "novel" PKCs (epsilon , delta , theta , and eta ), which are calcium-independent but diacylglycerol- and phorbol ester-sensitive; and "atypical" PKCs (zeta , and iota /lambda ), which are insensitive to calcium, diacylglycerol, and PMA. In addition, two related phospholipid-dependent kinases, PKCµ and protein kinase D, share sequence homology in their regulatory domains to novel PKCs and may constitute a new subgroup (3, 4).

Several studies with tumor-promoting phorbol esters suggest that PKC modulates neural differentiation. Phorbol esters induce neural tissue from ectoderm in Xenopus embryos (5) and elicit neurite outgrowth from chick sensory ganglia (6, 7), chick ciliary ganglion neurons (8), several human neuroblastoma cell lines (9, 10), and rat PC12 cells (11, 12). Studies using purified isozymes, kinase-defective mutants, and transgenic or mutant cell lines have implicated PKCalpha , -beta , -delta , -epsilon , and -zeta in the differentiation of nonneural cells (13-17). Overexpression of PKCalpha or -beta in Xenopus embryos enhances neural induction (18), but little else is known about the identity of specific PKC isozymes that regulate neural differentiation.

Recent evidence suggests that PKCepsilon plays a role in neural differentiation and plasticity. PKCepsilon is expressed predominantly in the nervous system and is particularly abundant in the hippocampus, olfactory tubercle, and layers I and II of cerebral cortex (19). Within immunoreactive neurons, it is localized to the Golgi apparatus and to axons and presynaptic nerve terminals (19). PKCepsilon is activated by growth factors that stimulate neural differentiation such as insulin (20) and NGF (21). In addition, in developing chick brain, it is the major isozyme found in nondividing, differentiating neurons (22).

Further evidence for involvement of PKCepsilon in neural differentiation has come from studies with PC12 cells. PC12 cells are derived from neural crest and, when treated with NGF or fibroblast growth factors, undergo dramatic biochemical and morphological differentiation, developing several characteristics of mature sympathetic neurons (23). PKC-activating phorbol esters enhance NGF-induced activation of ERK1 and ERK2 mitogen-activated protein (MAP) kinases and neurite outgrowth in PC12 cells, suggesting that PKC modulates responses to NGF (11, 12, 24). Studies with ethanol-treated PC12 cells helped direct us toward the PKC isozyme responsible for this effect. Like phorbol esters, ethanol increases NGF-induced MAP kinase activation and neurite outgrowth through a PKC-dependent mechanism (11, 24). Ethanol promotes PKC-mediated phosphorylation in PC12 cells by increasing levels of messenger RNA and protein for two PKC isozymes, PKCdelta and PKCepsilon (25, 26). Recently, we found that overexpression of PKCepsilon , but not of PKCdelta , enhances NGF-induced MAP kinase activation and neurite outgrowth (27). These findings establish PKCepsilon as a positive modulator of neurite growth. They also suggest that PKCepsilon mediates the neurite-promoting effect of ethanol and phorbol esters in PC12 cells. However, proof of this hypothesis requires studies with PKC isozyme-specific inhibitors or cells lacking specific PKC isozymes.

In the current study, we used specific inhibitors of PKCdelta and PKCepsilon to investigate whether PKCepsilon mediates enhancement of neurite outgrowth by phorbol esters and ethanol. To achieve this goal we used dominant-negative inhibitors based on the amino acid sequences for PKCdelta and PKCepsilon . This approach is based on the observation that upon activation, PKC isozymes translocate to specific intracellular sites where they appear to bind anchoring proteins, termed RACKs (receptors for activated C-kinase) (28). One such protein that has been cloned is RACK1, which interacts with the C2 domain of conventional PKCs (29). The sites of interaction between RACK1 and the C2 domain of PKCbeta have been mapped, and short peptides derived from these domains inhibit translocation and activation of PKCbeta in cardiac myocytes and Xenopus oocytes (29-31). Homology has been noted between the unique first variable region of PKCepsilon (epsilon V1) and the C2 domain of conventional PKCs (32), suggesting that, similar to the C2 domain of conventional PKCs, epsilon V1 may contain a binding site for an PKCepsilon -specific RACK. If that is the case, then expression of an epsilon V1 fragment should inhibit PKCepsilon translocation and function. Indeed, recent work has shown that an epsilon V1 fragment and a peptide corresponding to amino acids 14-21 in this region prevent phorbol ester-induced PKCepsilon translocation and inhibition of contraction in cultured cardiac myocytes (33).

In this paper, we describe studies with PC12 cell lines that stably express the fragments epsilon V1 or delta V1, which are derived from the first variable domains of PKCepsilon or PKCdelta , respectively. We found that each fragment selectively inhibited phorbol ester-induced translocation of its corresponding isozyme, indicating that these fragments can function as isozyme-selective translocation inhibitors. NGF-induced MAP kinase phosphorylation and neurite outgrowth were not enhanced by phorbol esters or ethanol in cells expressing epsilon V1, but they were increased by these agents in cells expressing delta V1 and in cells transfected with empty vector. These results demonstrate that PKCepsilon specifically mediates enhancement of MAP kinase activation and neurite growth by phorbol esters and ethanol in PC12 cells.


EXPERIMENTAL PROCEDURES

Materials

NGF (2.5 S) was purchased from Collaborative Research (Bedford, MA). Geneticin (G418), laminin, and poly-L-ornithine (30-70 kDa) were purchased from Sigma. Phorbol 12-myristate 13-acetate (PMA) was from LC Laboratories (Woburn, MA). Antibodies were purchased from the following sources: peroxidase-conjugated goat anti-rabbit IgG from Boehringer Mannheim, fluorescein-conjugated goat anti-rabbit IgG from Cappel (Durham, NC), anti-phospho-MAP kinase antibody from New England Biolabs (Beverly, MA), and anti-Flag M2 antibody from Eastman Kodak Co.

Cell Culture

PC12 cells, originally obtained from Dr. John A. Wagner (Cornell University, New York, NY), were cultured in plastic tissue culture flasks at 37 °C in Dulbecco's modified Eagle's medium containing 10% heat-inactivated horse serum, 5% fetal calf serum, 2 mM glutamine, 50 units/ml penicillin, and 50 µg/ml streptomycin, in a humidified atmosphere of 90% air and 10% CO2. For studies of neurite outgrowth, cells were plated at a density of 30-40 × 103 cells/well on 24-well plastic culture plates pretreated for 1 h with poly-L-ornithine (100 µg/ml in 15 mM sodium borate, pH 8.4). In some experiments, cells were plated at a density of 20 × 103 cells/well in 8-well glass chamber slides (Nunc, Naperville, IL) treated first with poly-L-ornithine and then laminin (30 µg/ml) overnight. Cells were cultured in medium containing 50 ng/ml of NGF for 4 days, and neurites were measured as described previously (27). Ethanol-treated cultures were wrapped in Parafilm to prevent evaporation of ethanol, as in prior studies (24, 25).

Immunofluorescence Microscopy

To detect PKCepsilon immunoreactivity, cells plated on glass chamber slides were incubated in PBS (137 mM NaCl, 2.7 mM KCl, 1.47 mM KH2PO4 8 mM Na2HPO4, 0.5 mM MgCl2, 0.9 mM CaCl2, pH 7.2) containing 2% paraformaldehyde for 30 min and 4% paraformaldehyde for 30 min at 4 °C. Cells were washed three times in PBS and incubated for 2 h in PBS containing 1% normal goat serum and 0.1% Triton X-100. Cells were incubated 48 h at 4 °C in PBS containing 2 mg/ml of bovine serum albumin, 0.1% Triton X-100, and 2 µg/ml of rabbit anti-PKCepsilon antibody (34) provided by Dr. Susan C. Kiley (W. Alton Jones Cell Science Center, Lake Placid, NY). Cells were washed three times in PBS, and immunoreactivity was detected using fluorescein-conjugated goat anti-rabbit IgG as described previously (27). Images were detected using a liquid-cooled CCD camera (Photometrics Ltd., Tucson, AZ) fitted with a Thompson 7883 chip (384 × 576 pixels) attached to an Olympus IMT-2 inverted microscope equipped with a × 60 1.3 numerical aperture objective. Exposure times were 0.5 s, and images were stored on an Apple Macintosh Quadra 950 computer. Fluorescence intensity in growth cones and cytoplasm was measured using the program BDS Image (Oncor Imaging Systems, Gaithersburg, MD).

To detect PKCdelta immunoreactivity, cells were incubated with rabbit polyclonal antibody against PKCdelta (0.2 µg/ml) from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) as described previously (27). Immunofluorescence in 0.5-µm optical sections was detected with a Bio-Rad MRC 1024 confocal laser-scanning microscope equipped with a Nikon × 60, 1.4 numerical aperture oil immersion objective. Nuclei were stained by incubating cells in PBS containing 2 mg/ml of bovine serum albumin, 0.1% Triton X-100, and 0.2 µM TOTO-3 (Molecular Probes, Eugene, OR) for 2 h at 25 °C. After three washes in PBS, slides were dried, and coverslips were mounted with Vectashield (Vector, Burlingame, CA). TOTO-3 immunofluorescence was detected by confocal laser-scanning microscopy. Images were analyzed in BDS Image to measure the area of each nucleus at its widest diameter.

Generation of Cell Lines

The plasmid pDM27 (33), containing a Flag-epitope tag followed by the sequence encoding amino acids 2-144 of PKCepsilon was used to amplify a 480-base pair fragment containing a NotI site at the 5'-end and a XbaI site at the 3'-end. This amplified fragment, containing an ATG start codon, the Flag epitope sequence, and the PKCepsilon sequence, was subcloned into the NotI and XbaI sites of pRc/RSV (Invitrogen, San Diego, CA) to generate the plasmid pRepsilon V-1. Another plasmid, pDM68 (33), containing the Flag epitope followed by the sequence encoding amino acids 2-144 of PKCdelta was used to amplify and subclone a homologous Flag-tagged PKCdelta sequence into pRc/RSV to generate the plasmid pRdelta V-1. PC12 cells (107) were suspended in 0.5 ml of Ca2+- and Mg2+-free PBS containing 137 mM NaCl, 2.7 mM KCl, 1.47 mM KH2PO4, 8 mM Na2HPO4, pH 7.2, and were electroporated with 80 µg of pRepsilon V-1, pRdelta V-1, or pRc/RSV as described previously (27). Geneticin was initially added at 400 µg/ml to select clones and later was added at 200 µg/ml to maintain cultures. For each vector, 46 clones were selected, expanded, and then examined for expression of Flag-tagged PKC fragment mRNA using RT-PCR and for Flag immunoreactivity by Western analysis.

RT-PCR

Poly(A) mRNA was isolated from 106 cells using a Micro-Fast Track mRNA isolation kit (Invitrogen, San Diego, CA). Reverse transcription was carried out with 100 ng of mRNA using a Stratagene (La Jolla, CA) RT-PCR kit according to the manufacturer's protocol. Amplification of cDNA was achieved using the forward primer (5'-ACACTGGCGGCCGCATGGACTACAAGGACGACGAT-3') and the reverse primers 5'-AGCGAGCTCTAGATCGTTCTTCATTGTCTTTA-3' for pRepsilon V-1, and 5'-ACAGACCTCTAGAGCGGTTCATAGTTGGGAA-3' for pRdelta V-1. These primers were designed to specifically amplify the Flag-V1 sequences and not the V1 sequences of endogenous PKCdelta and PKCepsilon in cells. Samples were heated to 94 °C, and amplification was started by the addition of Taq DNA polymerase. The amplification cycle was as follows: annealing for 45 s at 48 °C; elongation for 2 min at 72 °C, and denaturation for 1 min at 94 °C. Amplification was repeated for 30 cycles.

Western Analysis for Flag and Phospho-MAP Kinase Immunoreactivity

To detect expression of Flag-tagged peptides, cells were cultured on poly-L-ornithine-coated, 100-mm tissue culture dishes at a density of 6 × 106 cells/dish. Medium was removed, and cells were rinsed twice at 4 °C with buffer A (120 mM NaCl, 5 mM KCl, 1.4 mM CaCl2, 0.8 mM MgSO4, 1 mM NaH2PO4, 10 mM glucose, 25 mM HEPES, pH 7.4). Cells were scraped into 1 ml of buffer A containing 40 µg/ml leupeptin, 40 µg/ml soybean trypsin inhibitor, and 1 mM phenylmethylsulfonyl fluoride and then were frozen on dry ice. Concentrated 5 × sample buffer was added to 400-µl frozen samples to yield a final solution containing 62.5 mM Tris-HCl (pH 6.8), 2% SDS, 10% glycerol, 5% 2-mercaptoethanol, and 12.5 mg/ml bromphenol blue. Samples were heated at 90 °C for 10 min, passed five times through a 26-gauge needle, and centrifuged at 10,000 × g for 10 min. Samples (80 µg/lane) were separated by SDS-polyacrylamide gel electrophoresis using 14% gels. Proteins were electrophoretically transferred for 2 h at 4 °C to Hybond-C extra membranes (Amersham Corp.). Membranes were blocked for 1 h with 3% nonfat dry milk dissolved in Tris-buffered saline (TBS; 20 mM Tris HCl, pH 7.4, 137 mM NaCl). Blots were then incubated with anti-Flag M2 antibody (10 µg/ml) for 2 h at 25 °C. Blots were washed three times with TBS containing 0.05% Tween-20 (TBS-T) for two minutes and then were incubated with goat anti-mouse IgG-peroxidase-conjugated antibody (1:1000 dilution) in blocking solution overnight at 25 °C. Blots were washed three times for 15 min in TBS-T and once with TBS. Immunoreactive bands were detected with the ECL kit from Amersham.

Activation of ERK1 and ERK2 MAP kinases was assayed with a phospho-specific 42/44-kDa MAP kinase rabbit polyclonal antibody raised against a phosphotyrosine peptide corresponding to residues 196-209 of human ERK1. The antibody detects phosphorylation of ERK1 at tyrosine 204, which is required for ERK1 activation (35). The antibody also detects phosphorylation of the corresponding activating tyrosine of ERK2. Blots from 11% polyacrylamide gels were washed for 5 min with 25 ml of buffer B containing 58 mM Na2HPO4, 17 mM NaH2PO4, and 68 mM NaCl, pH 7.4. Membranes were blocked in buffer B containing 0.1% Tween 20 and 5% milk (blocking buffer) for 1 h. Blots were incubated overnight at 4 °C with 1 µg/ml of anti-phospho-MAP kinase antibody in buffer B containing 0.05% Tween 20 and 5% bovine serum albumin (incubation buffer). They were then washed three times for 5 min with 15 ml of blocking buffer and incubated with goat anti-rabbit alkaline phosphatase-conjugated antibody (1:2000 dilution) in incubation buffer for 1 h at 25 °C. Blots were finally washed three times with 15 ml of blocking buffer, and immunoreactive bands were detected using the Western-Light chemiluminescent detection system from Tropix, Inc. (Bedford, MA).

PKC Translocation

Cells (3-4 × 106) were plated on 100-mm plastic tissue culture plates. After 48 h, cultures were rinsed at 37 °C twice with 10 ml of medium and incubated with or without 30 nM PMA for 2 min. Cells were rapidly rinsed twice at 4 °C with Ca2+- and Mg2+-free PBS and then were scraped into 1 ml of ice-cold buffer C containing 20 mM Tris HCl, pH 7.5, 2 mM EDTA, 10 mM EGTA, 40 µg/ml leupeptin, 40 µg/ml aprotinin, 20 µg/ml soybean trypsin inhibitor, and 1 mM phenylmethylsulfonyl fluoride. Cells were homogenized at 4 °C with 10 strokes of a Teflon-glass homogenizer. Sucrose was added to a final concentration of 250 mM, and the sample was homogenized with 10 additional strokes. An aliquot of 800 µl was centrifuged at 150,000 × g for 1 h, and the supernatant was frozen on dry ice. The pellet was dispersed in 800 µl of buffer C by sonication in a Branson Sonifier 450 for 2 s at a setting of six. Samples of supernatant and pellet suspension derived from 100 µg of crude homogenate were separated by SDS-polyacrylamide gel electrophoresis using 10% gels and analyzed for PKCdelta and PKCepsilon immunoreactivity by Western analysis as described previously (27).

Miscellaneous Procedures

Protein concentrations were measured by the Bradford method (36) using bovine IgG standards. Results are expressed as mean ± S.E. values, and differences between means were analyzed by ANOVA. Where p < 0.05, the significance of differences between means was evaluated by the Scheffe F-test or the Newman Keuls test.


RESULTS

Analysis of Transfected Cells

Stably transfected PC12 clones were tested for expression of the first variable domain of PKCdelta or PKCepsilon by RT-PCR (Fig. 1A) and Western analysis (Fig. 1B). Two clones, V1delta 1 and V1delta 2, expressing the V1 region of PKCdelta (delta V1), and two clones, V1epsilon 1 and V1epsilon 2, expressing the V1 region of PKCepsilon (epsilon V1), were expanded for further studies.


Fig. 1. RT-PCR and Western analysis of transfected PC12 cells demonstrating expression of delta V1 and epsilon V1 fragments. PC12 cells were transfected with the parent vector pRc/RSV (C1), the vector pRdelta V-1 containing the cDNA sequence for delta V1 (V1delta 1, V1delta 2), or with pRepsilon V-1 containing the cDNA sequence for epsilon V1 (V1epsilon 1, V1epsilon 2). A, 1.2% agarose gels of RT-PCR products showing expression of delta V1 fragment mRNA in clones V1delta 1 and V1delta 2 and epsilon V1 fragment mRNA in clones V1epsilon 1 and V1epsilon 2. No delta V1 mRNA or epsilon V1 mRNA (not shown) was detected in C1 cells. B, Western blots showing 17-kDa Flag immunoreactivity in clones V1delta 1 and V1delta 2 and in clones V1epsilon 1 and V1epsilon 2, co-migrating with purified Flag-tagged epsilon V1 expressed in bacteria (epsilon V1 fragment). The same molecular mass was detected for Flag-tagged delta V1 purified from bacteria (not shown). Std, DNA size markers.
[View Larger Version of this Image (60K GIF file)]

To determine whether the delta V1 and epsilon V1 fragments expressed by our PC12 clones act as PKC isozyme-selective inhibitors, we measured PMA-induced translocation of PKCdelta and PKCepsilon to the particulate fraction of these cells. We predicted that if delta V1 contains a binding site for a PKCdelta -specific RACK, it should inhibit translocation of PKCdelta . Likewise, if epsilon V1 interacts with an PKCepsilon -specific RACK, then expression of epsilon V1 should block phorbol ester-mediated translocation of PKCepsilon . In the parent PC12 cell line and in cells transfected with the pRc/RSV vector alone (clone C1), 30 nM PMA stimulated translocation of PKCdelta and PKCepsilon to the particulate fraction (Fig. 2). In V1delta 1 and V1delta 2 cells, which express the delta V1 peptide, 30 nM PMA stimulated translocation of PKCepsilon , but translocation of PKCdelta was reduced in these clones (Fig. 2, A and B). In V1epsilon 1 and V1epsilon 2 cells, 30 nM PMA stimulated translocation of PKCdelta , but translocation of PKCepsilon was reduced compared with control cells (Fig. 2, A and C). These results demonstrate that delta V1 and epsilon V1 fragments selectively inhibit PMA-induced translocation of their corresponding PKC isozymes.


Fig. 2. The epsilon V1 and delta V1 fragments selectively inhibit PMA-induced translocation of their parent PKC isozymes in transfected cells. PKCdelta and PKCepsilon immunoreactivity in cytosol (C) and particulate (P) fractions was detected by Western analysis following treatment without or with 30 nM PMA for 2 min. A, representative Western blots showing PKCdelta and PKCepsilon immunoreactivity in PC12, V1delta 1, and V1epsilon 1 cells. B, the percentage of PKCdelta or PKCepsilon immunoreactivity that translocated to the particulate fraction following treatment with PMA. Values were calculated by subtracting the percentage of total PKC immunoreactivity present in the particulate fraction of cells treated with PMA from the percentage in the particulate fraction of untreated cells. Data are from 4-7 experiments. *, p < 0.05 compared with PC12 and C1 cells by ANOVA and the Newman-Keuls test.
[View Larger Version of this Image (57K GIF file)]

PKC Immunoreactivity in Cells Expressing V1 Fragments

We attempted to examine cells by indirect immunofluorescence with anti-Flag antibody to determine the subcellular localization of expressed delta V1 and epsilon V1 but were unsuccessful because of high background staining. We next examined the subcellular localization of endogenous PKCdelta and PKCepsilon to determine whether their localization was altered by expression of delta V1 or epsilon V1. In undifferentiated cells, PKCdelta and PKCepsilon immunoreactivity was observed throughout the cytoplasm, as previously reported (27) and was not altered in clones expressing delta V1 or epsilon V1 (data not shown). In PC12 and C1 cells treated with 50 ng/ml of NGF for 4 days, most PKCdelta immunoreactivity was observed in the cytosol, asymmetrically next to the nucleus (Fig. 3). Less intense staining was seen in a thin perinuclear band and within nuclei. In the majority of V1delta 1 and V1delta 2 cells expressing delta V1, most PKCdelta immunoreactivity appeared in the perinuclear region (Fig. 3). In addition, nuclei appeared larger in these cells. This was analyzed further using confocal images of TOTO-3-stained nuclei at their widest diameter. Nuclei were of similar size in PC12 (82.8 ± 1.5 µm2; n = 164) and C1 (88.3 ± 2.1 µm2; n = 145) cells but were significantly larger in V1delta 1 (106.4 ± 3.8 µm2; n = 88) and V1delta 2 (100.6 ± 2.8 µm2; n = 172) cells (p < 0.05 compared with PC12 and C1 nuclei; ANOVA and Scheffe-F test).


Fig. 3. Indirect immunofluorescence of PKCdelta in V1delta -expressing cells. PC12 cells (PC) and cells transfected with vector alone (C1), or pRdelta V-1 (V1delta 1 and V1delta 2) were cultured for 4 days with 50 ng/ml of NGF and then immunostained with antibody to PKCdelta . The arrowheads show PKCdelta immunoreactivity present asymmetrically next to nuclei of PC12 and C1 cells. The arrows show perinuclear PKCdelta immunoreactivity in V1delta 1 and V1delta 2 cells. Bar, 25 µm.
[View Larger Version of this Image (125K GIF file)]

Following treatment with NGF, PKCepsilon immunoreactivity was observed in growth cones, neurite shafts, and the cytoplasm of the cell soma in PC12 and C1 cells (Fig. 4), as noted previously (27). In V1epsilon 1 and V1epsilon 2 cells expressing epsilon V1, PKCepsilon immunoreactivity was reduced in growth cones and neurite shafts (Fig. 4). This was examined further by calculating the ratio of mean fluorescence intensity of each growth cone and of the cytoplasm at the base of its neurite shaft. In PC12 (0.73 ± 0.02; n = 71) and C1 (0.76 ± 0.02; n = 55) cells, this ratio was significantly greater (p < 0.05; ANOVA and Scheffe F-test) than ratios measured in V1epsilon 1 (0.49 ± 0.01; n = 83) and V1epsilon 2 (0.50 ± 0.01; n = 71) cells. These results demonstrate that epsilon V1 and delta V1 fragments alter the localization of their corresponding PKC isozymes in cells undergoing NGF-induced differentiation. In addition, expression of delta V1 is associated with an increase in nuclear size.


Fig. 4. Indirect immunofluorescence of PKCepsilon in V1epsilon -expressing cells. Parent PC12 cells (PC) and cells transfected with the empty pRc/RSV vector (C1) or pRepsilon V-1 (V1epsilon 1 and V1epsilon 2) were cultured for 4 days with 50 ng/ml NGF prior to fixation and immunostaining with antibody against PKCepsilon . The arrows show prominent PKCepsilon immunoreactivity in growth cones of PC12 and C1 cells and reduced immunoreactivity in growth cones of V1epsilon 1 and V1epsilon 2 cells. Bar, 30 µm.
[View Larger Version of this Image (95K GIF file)]

Growth and Neurite Formation in Cell Lines Expressing delta V1 or epsilon V1

The growth rates of V1delta - and V1epsilon -expressing clones, parent PC12 cells, and C1 cells were similar before NGF treatment (data not shown). After culture in poly-L-ornithine-treated culture dishes with 50 ng/ml NGF for 4 days, the number of neurite-bearing cells and the length of neurites was similar in all cell lines (Tables I and II). However, in NGF-treated V1epsilon 1 and V1epsilon 2 cells, neither ethanol nor PMA (10 nM) increased neurite length or the percentage of cells that expressed neurites. In contrast, ethanol and PMA increased neurite length and the percentage of neurite-bearing cells in NGF-treated PC12, C1, V1delta 1, and V1delta 2 cultures. When cells were cultured on glass slides treated with poly-L-ornithine and coated with laminin, the results were qualitatively similar but more dramatic because NGF-induced neurite outgrowth was especially robust following treatment with ethanol or PMA in all but V1epsilon 1 and V1epsilon 2 cultures (Fig. 5, A and B). Therefore, expression of the epsilon V1 fragment, but not of the delta V1 fragment, appears to prevent enhancement of neurite extension by PMA or ethanol in NGF-treated cells.

Table I. Percentage of cells expressing neurites after treatment with NGF plus PMA or ethanol

Cells were cultured on polyornithine-coated tissue culture dishes with or without 100 mM ethanol for 6 days and then with 50 ng/ml NGF in the continued presence or absence of ethanol for another 4 days. Additional cells were cultured with NGF and 10 nM PMA for 4 days without ethanol. The percentage of cells with neurites was calculated from 80-120 cells/condition in 3-5 experiments.

Cell line NGF NGF + PMA NGF + ethanol

PC12 38  ± 1 57  ± 1a 60  ± 2a
C1 38  ± 1 56  ± 2a 60  ± 2a
V1delta 1 36  ± 1 56  ± 2a 62  ± 2a
V1delta 2 40  ± 1 59  ± 1a 62  ± 1a
V1varepsilon 1 32  ± 2 30  ± 1 33  ± 3
V1varepsilon 2 40  ± 1 40  ± 1 43  ± 1

a Significantly different compared with treatment with NGF alone (ANOVA and Scheffe F-test).

Table II. Neurite length after treatment with NGF plus PMA or ethanol

Cells were cultured on polyornithine-coated tissue culture dishes with or without 100 mM ethanol for 6 days and then with 50 ng/ml NGF in the continued presence or absence of ethanol for another 4 days. Additional cells were cultured with NGF and 10 nM PMA for 4 days without ethanol. Neurite length is expressed in µm and was determined by measuring 100 neurites/condition in a representative experiment repeated three times.

Cell line NGF NGF + PMA NGF + ethanol

PC12 24.7  ± 1.5 47.6  ± 2.9a 46.4  ± 2.8a
C1 23.6  ± 1.8 42.6  ± 2.4a 43.8  ± 3.2a
V1delta 1 24.2  ± 1.6 39.3  ± 2.4a 46.5  ± 2.4a
V1delta 2 24.2  ± 1.6 44.8  ± 2.1a 46.8  ± 2.9a
V1varepsilon 1 21.7  ± 1.4 27.4  ± 1.7 22.5  ± 1.4
V1varepsilon 2 21.1  ± 1.7 29.0  ± 1.9 27.9  ± 1.9

a Significantly different compared with cells treated with NGF alone (ANOVA and Scheffe F-test).


Fig. 5. Morphology of wild type and delta V1 and epsilon V1 transfected PC12 cells after NGF treatment. Parent PC12 cells (PC) and cells transfected with the empty pRc/RSV vector (C1), pRdelta V-1 (V1delta 1 and V1delta 2), or pRepsilon V-1 (V1epsilon 1 and V1epsilon 2) were cultured on polyornithine- and laminin-treated glass coverslips for 4 days with 50 ng/ml of NGF (a, d, g, j, m, and p) or with NGF and 10 nM PMA (b, e, h, k, n, and q). Some cultures were pretreated with 100 mM ethanol for 6 days before NGF was added in the continued presence of ethanol (c, f, i, l, o, and r). Cells were visualized by transmitted light interference contrast microscopy. Bar, 25 µm.
[View Larger Version of this Image (118K GIF file)]

MAP Kinase Phosphorylation in PKC-transfected Cells

NGF and basic fibroblast growth factor stimulate sustained activation of ERK1 and ERK2 MAP kinases in PC12 cells, which is important for their neuronal differentiation (37). Previous work has shown that treatment with either PMA or ethanol increases NGF-induced phosphorylation and activation of ERK1 and ERK2 (24). Since overexpression of PKCepsilon also enhances NGF-induced MAP kinase phosphorylation (27), we examined whether expression of epsilon V1 would prevent enhancement of MAP kinase activation by PMA or ethanol.

ERK1 and ERK2 are activated by dual phosphorylation on neighboring tyrosine and threonine residues (35). We measured activation of ERK1 and ERK2 by Western analysis using an anti-phospho-MAP kinase antibody that specifically detects phosphorylation of the activating tyrosine of each enzyme. As described previously in PC12 cells (24), NGF stimulated phosphorylation of ERK1 and ERK2 in C1 cells with a biphasic time course (Fig. 6A). Phosphorylation was maximal after 5-10 min (peak phase) and then declined to a lower level (plateau phase) that was maintained for at least 2 h. A similar pattern of phosphorylation was observed in V1delta 1, V1delta 2, V1epsilon 1, and V1epsilon 2 cells (Fig. 6). As previously observed in PC12 cells (24), co-treatment with 10 nM PMA or pretreatment with 100 mM ethanol for 6 days increased NGF-induced ERK phosphorylation. This was particularly evident during the plateau phase of ERK phosphorylation, which was elevated to levels achieved during the peak phase in C1 and V1delta 2 cells (Fig. 6A). A similar increase in phosphorylation was also observed in V1delta 1 cells (Fig. 6, B and C). In contrast, the plateau phase of ERK phosphorylation was not increased in V1epsilon 1 or V1epsilon 2 cells treated with ethanol or PMA (Fig. 6, A-C). Therefore, expression of the epsilon V1 fragment specifically inhibits PMA- or ethanol-induced ERK phosphorylation in NGF-treated cells.


Fig. 6. The epsilon V1 fragment prevents enhancement of NGF-stimulated MAP kinase phosphorylation by PMA or ethanol. PC12 cells transfected with the empty pRc/RSV vector (C1), pRdelta V-1 (V1delta 1), or pRepsilon V-1 (V1epsilon 1) were treated with 50 ng/ml of NGF alone (NGF) or with NGF and 10 nM PMA (NGF + PMA). Some cells were pretreated with 100 mM ethanol for 6 days prior to the addition of NGF in the continued presence of ethanol (NGF + EtOH). Tyrosine phosphorylation of ERK1 and ERK2 was detected by Western analysis of cell lysates using an anti-phospho-MAP kinase antibody. A, Western blots showing the time course of ERK1 (upper band) and ERK2 (lower band) tyrosine phosphorylation in clones C1, V1delta 2, and V1epsilon 1. Similar results were observed in clones V1delta 1 and V1epsilon 2 and in parent PC12 cells (data not shown). B and C, quantitation of ERK1 (B) and ERK2 (C) phosphorylation in C1 control cells and in V1 fragment-transfected cells after 60 min of treatment with 50 ng/ml NGF (open bars), NGF and PMA (black bars), or NGF and ethanol (gray bars). Data are expressed as a percentage of maximal phospho-ERK1 or phospho-ERK2 immunoreactivity observed after 5-10 min of NGF treatment and are from 2-4 experiments. Immunoreactivity was significantly increased by treatment with PMA or ethanol only in C1, V1delta 1, and V1delta 2 cells but not in V1epsilon 1 or V1epsilon 2 cells (ANOVA, Scheffe F-test).
[View Larger Version of this Image (59K GIF file)]


DISCUSSION

The current results identify PKCepsilon as the PKC isozyme responsible for enhancement of NGF responses by phorbol esters and ethanol in PC12 cells. We previously found that phorbol esters enhance NGF-induced neurite outgrowth and MAP kinase activation in PC12 cells (11, 24). Ethanol also increases these responses to NGF by a PKC-dependent mechanism (11, 24). Recently, we found that overexpression of PKCepsilon also enhances responses to NGF (27), suggesting that PKCepsilon mediates the neurite-promoting effect of PMA and ethanol. In this paper, we investigated this issue directly, by creating PC12 cell lines that express peptides encoding V1 domains of PKCdelta or PKCepsilon , which act as isozyme-selective translocation inhibitors (33). We found that expression of the epsilon V1 fragment selectively inhibited PMA-induced translocation of PKCepsilon , whereas expression of the delta V1 fragment specifically inhibited translocation of PKCdelta . Cells expressing these peptides showed no alterations in cell growth. However, expression of epsilon V1 prevented enhancement of NGF-induced MAP kinase activation and neurite growth by PMA or ethanol. In contrast, expression of delta V1 did not alter enhancement of NGF responses by these agents. These findings indicate that PKCepsilon mediates enhancement of neurite outgrowth and MAP kinase activation by PMA or ethanol in NGF-treated PC12 cells.

Our data are consistent with a recent study (33) in which a delta V1 fragment, an epsilon V1 fragment, and an epsilon V1-derived peptide were introduced into cardiac myocytes by transient permeabilization. These fragments selectively inhibited PMA-induced translocation of their corresponding PKC isozyme and not translocation of other isozymes concomitantly activated in these cells. Furthermore, the epsilon V1 fragment and the short peptide derived from it inhibited phorbol ester- or hormone-induced regulation of contraction rate, whereas the delta V1 fragment or translocation inhibitors of PKCbeta did not. Together with the data presented here, these studies reinforce the concept that translocation of PKC is required for its function (28) and indicate that isozyme-selective inhibitors of PKC translocation can be used to determine the function of individual isozymes in a variety of cells.

The ability of the PKCdelta and -epsilon fragments to act as isozyme-selective translocation inhibitors is also consistent with the hypothesis that each contains a binding site for a corresponding, isozyme-specific RACK (28). This hypothesis is further supported by the finding of structural homology between epsilon V1 (32) and the C2 domain of conventional PKCs, which contains a RACK1 binding site (29). Indeed, an PKCepsilon -specific RACK, RACK2, that has recently been cloned, binds the epsilon V1 fragment in vitro.2

Prominent PKCepsilon immunoreactivity was found in neurites and growth cones of NGF-treated parent PC12 and C1 cells. This was reduced in processes of cells expressing epsilon V1, suggesting that epsilon V1 displaces endogenous PKCepsilon from binding sites in neurites and growth cones. Localization of PKCepsilon to growth cones is consistent with a role for this isozyme in regulating neurite outgrowth (38). Immunoprecipitation-kinase assays indicate that NGF activates PKCepsilon in PC12 cells (21), suggesting that NGF-induced localization of PKCepsilon to neurites and growth cones may involve activation of this isozyme. This suggests that an PKCepsilon -specific RACK may reside in growth cones and neurites.

In PC12 and C1 control cells, PKCdelta immunoreactivity was most prominent asymmetrically next to the nucleus. Expression of delta V1 was associated with redistribution of PKCdelta immunoreactivity to the perinuclear region and with an increase in nuclear size. It is difficult to speculate on the physiologic significance of these changes, since the function of PKCdelta in these cells is not yet known. However, the findings clearly indicate that delta V1 alters the localization of PKCdelta and produces a unique change in cell morphology.

NGF-induced activation of ERK1 and ERK2 involves phosphorylation and binding of phospholipase Cgamma and the adapter protein Shc to the NGF receptor tyrosine kinase TrkA (39). Within minutes of NGF binding, phosphorylated Shc also forms a complex with another adapter protein, Grb2, and with the guanine nucleotide exchange factor mSOS (40), leading to activation of Ras (41) and sequential activation of B-Raf (42), MAP kinase kinase-1 (43, 44), and ERK1 and ERK2 (45). This pathway appears essential for NGF-induced neurite outgrowth, since dominant negative inhibitors of Ras (46) or MAP kinase kinase-1 (47) block NGF-induced neurite outgrowth in PC12 cells. PKCepsilon could enhance ERK activation by increasing the activity of members of this pathway. For example, PKCalpha appears to phosphorylate and activate Raf-1 (48), suggesting that other PKC isozymes, such as PKCepsilon , might also modulate Raf kinases. In addition, NGF stimulates binding of Shc to F-actin in PC12 cells (49). NGF also activates PKCepsilon (21), and upon activation, PKCepsilon binds F-actin in nerve terminals (50). This raises the intriguing possibility that Shc or proteins complexed with Shc interact with PKCepsilon when both Shc and PKCepsilon are anchored to actin. We do not yet know if the epsilon V1 fragment prevents binding of PKCepsilon to actin, since actin binds to PKCepsilon at a site between the first and second cysteine-rich regions of the C1 domain, which is outside of the epsilon V1 domain (50). Whether binding of PKCepsilon to actin is important for regulation of MAP kinases and neurite outgrowth also remains to be determined.

The major effect of phorbol esters or overexpressed PKCepsilon is to increase the late plateau phase of MAP kinase activation rather than the initial peak phase (24, 27). These kinetics suggest that PKCepsilon may act by inhibiting dephosphorylation of ERK1 and ERK2 rather than by promoting ERK activation. MAP kinase phosphatase (MKP)-1, MKP-2, and hVH3 are dual specificity protein phosphatases that are expressed in the brain and dephosphorylate and inactivate ERKs (51, 52). MKP-1 and MKP-2 mRNAs are constitutively expressed at low levels in PC12 cells and are increased by NGF (51). Inhibition of MKP-1 expression in PC12 cells does not accelerate the early phase of MAP kinase inactivation following stimulation with growth factors (53). Instead, protein phosphatase 2A and an unidentified protein-tyrosine phosphatase appear to mediate the rapid phase of inactivation in these cells (54). The role of dual specificity phosphatases in regulating the later plateau phase of NGF-induced MAP kinase activation is not known, but NGF induction of mRNA for MKP-1 and MKP-2 peaks at 1-2 h (51), suggesting that they may regulate this phase. If this is the case, then inhibition of these phosphatases by PKCepsilon may account for enhanced activation of ERK1 and ERK2.

ERK activity is also regulated by negative feedback inhibition. Phosphorylation of mSOS by MAP kinase promotes dissociation of mSOS from tyrosine-phosphorylated Shc and epidermal growth factor receptors (55, 56). In addition, MAP kinase kinase-dependent phosphorylation of mSOS has been reported to cause dissociation of mSOS-Grb2 complexes, interrupting mSOS activation of Ras (57). Moreover, ERK1 phosphorylates MAP kinase kinase, and this phosphorylation appears to reduce MAP kinase kinase activity (58). Therefore, inhibition of mSOS or MAP kinase kinase retrophosphorylation may be mechanisms by which PKCepsilon could enhance MAP kinase activation.

Together with studies in primary neurons (20, 22, 59), our findings suggest that PKCepsilon modulates neural differentiation. This may be a mechanism for enhancement of neurite growth by neurotransmitters that activate receptors coupled to phospholipase C and could be important for activity-dependent remodeling of synapses during normal development (60). Our studies also suggest that excessive activation of PKCepsilon may contribute to abnormal neurite growth observed in certain disease states. Chronic abuse of ethanol can damage the nervous system by disrupting the growth and remodeling of dendrites and axons. In certain brain regions, ethanol increases the growth of neural processes and terminals (61-65). This is particularly striking in the hippocampus, where expression of PKCepsilon is high (19). There prenatal exposure to ethanol causes marked overgrowth of dentate granule cell axons (mossy fibers) into the stratum pyramidale and stratum oriens of CA3, which may contribute to cognitive dysfunction (65). In addition, abnormal growth of mossy fibers into the supragranular layer of the dentate gyrus is found in some humans with temporal lobe epilepsy and in animals following stimuli that induce epilepsy (66). Future studies with transgenic and PKCepsilon mutant mice or with epsilon V1-derived inhibitory peptides may allow us to examine the role of PKCepsilon in normal development, alcohol-related neurologic disorders, and epileptogenesis.


FOOTNOTES

*   This work was supported in part by National Institutes of Health (NIH) Grants AA 10036 and AA 08117 and a grant from the Alcoholic Beverage Medical Research Foundation (to R. O. M.), and NIH Grant HL 52141 (to D. M.-R).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§   These authors contributed equally to this work.
par    To whom correspondence should be addressed: E. Gallo Clinic & Research Center, University of California, Bldg. 1, Room 101, 1001 Potrero Ave., San Francisco, CA 94110. Tel.: 415-648-7111 (ext. 329); Fax: 415-648-7116; E-mail: romes{at}itsa.ucsf.edu.
1   The abbreviations used are: PKC, protein kinase C; PMA, phorbol 12-myristate 13-acetate; NGF, nerve growth factor; MAP, mitogen-activated protein; ERK, extracellular signal-regulated kinase; RACK, receptor for activated protein kinase C; PBS, phosphate-buffered saline; RT-PCR, reverse transcriptase-polymerase chain reaction; TBS, Tris-buffered saline; ANOVA, analysis of variance; MAPKK, MAP kinase kinase; MKP, MAP kinase phosphatase.
2   M. Csukai, C.-H. Chen, and D. Mochly-Rosen, manuscript in preparation.

REFERENCES

  1. Selbie, L. A., Schmitz-Peiffer, C., Sheng, Y., and Biden, T. J. (1993) J. Biol. Chem. 268, 24296-24302 [Abstract/Free Full Text]
  2. Nishizuka, Y. (1992) Science 258, 607-614 [Medline] [Order article via Infotrieve]
  3. Johannes, F.-J., Prestle, J., Eis, S., Oberhagemann, P., and Pfizenmaier, K. (1994) J. Biol. Chem. 269, 6140-6148 [Abstract/Free Full Text]
  4. Valverde, A. M., Sinnett-Smith, J., Van Lint, J., and Rozengurt, E. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 8572-8576 [Abstract]
  5. Otte, A. P., Koster, C. H., Snoek, G. T., and Durston, A. J. (1988) Nature 334, 618-620 [CrossRef][Medline] [Order article via Infotrieve]
  6. Mehta, S., Hsu, L., Jeng, A. Y., and Chen, K. Y. (1993) J. Neurochem. 60, 972-981 [Medline] [Order article via Infotrieve]
  7. Hsu, L., Natyzak, D., and Laskin, J. D. (1984) Cancer Res. 44, 4607-4614 [Abstract]
  8. Bixby, J. L. (1989) Neuron 3, 287-297 [Medline] [Order article via Infotrieve]
  9. Pahlman, S., Ruusala, A.-I., Abrahamsson, L., Odelstad, L., and Nilsson, K. (1983) Cell Differ. 12, 165-170 [CrossRef][Medline] [Order article via Infotrieve]
  10. Spinelli, W., Sonnenfeld, K. H., and Ishii, D. N. (1982) Cancer Res. 42, 5067-5073 [Abstract]
  11. Roivainen, R., McMahon, T., and Messing, R. O. (1993) Brain Res. 624, 85-93 [CrossRef][Medline] [Order article via Infotrieve]
  12. Hall, F. L., Fernyhough, P., Ishii, D. N., and Vulliet, P. R. (1988) J. Biol. Chem. 263, 4460-4466 [Abstract/Free Full Text]
  13. Berra, E., Diaz-Meco, M. T., Dominguez, I., Municio, M. M., Sanz, L., Lozano, J., Chapkin, R. S., and Moscat, J. (1993) Cell 74, 555-563 [Medline] [Order article via Infotrieve]
  14. Goodnight, J., Mischak, H., and Mushinski, J. F. (1994) Adv. Cancer Res. 64, 159-209 [Medline] [Order article via Infotrieve]
  15. Gruber, J. R., Ohno, S., and Niles, R. M. (1992) J. Biol. Chem. 267, 13356-13360 [Abstract/Free Full Text]
  16. Macfarlane, D. E., and Manzel, L. (1994) J. Biol. Chem. 269, 4327-4331 [Abstract/Free Full Text]
  17. Powell, C. T., Leng, L., Dong, L., Kiyokawa, H., Busquets, X., O'Driscoll, K., Marks, P. A., and Rifkind, R. A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 147-151 [Abstract]
  18. Otte, A. P., and Moon, R. T. (1992) Cell 68, 1021-1029 [Medline] [Order article via Infotrieve]
  19. Saito, N., Itouji, A., Totani, Y., Osawa, I., Koide, H., Fujisawa, N., Ogita, K., and Tanaka, C. (1993) Brain Res. 607, 241-248 [CrossRef][Medline] [Order article via Infotrieve]
  20. Heidenreich, K. A., Toledo, S. P., Brunton, L. L., Watson, M. J., Daniel-Issakani, S., and Strulovici, B. (1990) J. Biol. Chem. 265, 15076-15082 [Abstract/Free Full Text]
  21. Ohmichi, M., Zhu, G., and Saltiel, A. R. (1993) Biochem. J. 295, 767-772 [Medline] [Order article via Infotrieve]
  22. Mangoura, D., Sogos, V., and Dawson, G. (1993) J. Neurosci. Res. 35, 488-498 [Medline] [Order article via Infotrieve]
  23. Greene, L. A., Sobeih, M. M., and Teng, K. K. (1991) in Culturing Nerve Cells (Banker, G., and Goslin, K., eds), pp. 207-226, MIT Press, Cambridge, MA
  24. Roivainen, R., Hundle, B., and Messing, R. O. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 1891-1895 [Abstract]
  25. Messing, R. O., Petersen, P. J., and Henrich, C. J. (1991) J. Biol. Chem. 266, 23428-23432 [Abstract/Free Full Text]
  26. Roivainen, R., Hundle, B., and Messing, R. O. (1994) in Toward a Molecular Basis of Alcohol Use and Abuse (Jansson, B., Jörvall, H., Rydberg, U., Terenius, L., and Vallee, B. L., eds), pp. 29-38, Birkhäuser Verlag, Basel
  27. Hundle, B., McMahon, T., Dadgar, J., and Messing, R. O. (1995) J. Biol. Chem. 270, 30134-30140 [Abstract/Free Full Text]
  28. Mochly-Rosen, D. (1995) Science 268, 247-251 [Medline] [Order article via Infotrieve]
  29. Ron, D., Chen, C.-H., Caldwell, J., Jamieson, L., Orr, E., and Mochly-Rosen, D. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 839-843 [Abstract]
  30. Ron, D., Luo, J., and Mochly-Rosen, D. (1995) J. Biol. Chem. 270, 24180-24187 [Abstract/Free Full Text]
  31. Zhang, Z.-H., El-Sherif, N., Ron, D., Mochly-Rosen, D., and Boutjdir, M. (1996) Biophys. J. 70, A391
  32. Sossin, W. S., and Schwartz, J. H. (1993) Trends Biochem. Sci. 18, 207-208 [CrossRef][Medline] [Order article via Infotrieve]
  33. Johnson, J. A., Gray, M. O., Chen, C.-H., and Mochly-Rosen, D. (1996) J. Biol. Chem. 271, 24962-24966 [Abstract/Free Full Text]
  34. Kiley, S. C., and Parker, P. J. (1995) J. Cell Sci. 108, 1003-1016 [Abstract/Free Full Text]
  35. Robbins, D. J., Zhen, E., Owaki, H., Vanderbilt, C. A., Ebert, D., Geppert, T. D., and Cobb, M. H. (1993) J. Biol. Chem. 268, 5097-5106 [Abstract/Free Full Text]
  36. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254 [CrossRef][Medline] [Order article via Infotrieve]
  37. Marshall, C. J. (1995) Cell 80, 179-185 [Medline] [Order article via Infotrieve]
  38. Campenot, R. B., Draker, D. D., and Senger, D. L. (1994) J. Neurochem. 63, 868-878 [Medline] [Order article via Infotrieve]
  39. Stephens, R. M., Loeb, D. M., Copeland, T. D., Pawson, T., Greene, L. A., and Kaplan, D. R. (1994) Neuron 12, 691-705 [Medline] [Order article via Infotrieve]
  40. Basu, T., Warne, P. H., and Downward, J. (1994) Oncogene 9, 3483-3491 [Medline] [Order article via Infotrieve]
  41. Nakafuku, M., Satoh, T., and Kaziro, Y. (1992) J. Biol. Chem. 267, 19448-19454 [Abstract/Free Full Text]
  42. Jaiswal, R. K., Moodie, S. A., Wolfman, A., and Landreth, G. E. (1994) Mol. Cell. Biol. 14, 6944-6953 [Abstract]
  43. Jaiswal, R. K., Murphy, M. B., and Landreth, G. E. (1993) J. Biol. Chem. 268, 7055-7063 [Abstract/Free Full Text]
  44. Alessi, D. R., Saito, Y., Campbell, D. G., Cohen, P., Sithanandam, G., Rapp, U., Ashworth, A., Marshall, C. J., and Cowley, S. (1994) EMBO J. 13, 1610-1619 [Abstract]
  45. Boulton, T. G., Nye, S. H., Robbins, D. J., Ip, N. Y., Radziejewska, E., Morgenbesser, S. D., DePinho, R. A., Panayotatos, N., Cobb, M. H., and Yancopoulos, G. D. (1991) Cell 65, 663-675 [Medline] [Order article via Infotrieve]
  46. Thomas, S. M., DeMarco, M., D'Arcangelo, G., Halegoua, S., and Brugge, J. S. (1992) Cell 68, 1031-1040 [Medline] [Order article via Infotrieve]
  47. Cowley, S., Paterson, H., Kemp, P., and Marshall, C. J. (1994) Cell 77, 841-852 [Medline] [Order article via Infotrieve]
  48. Kolch, W., Heidecker, G., Kochs, G., Hummel, R., Vahidi, H., Mischak, H., Finkenzeller, G., Marmé, D., and Rapp, U. R. (1993) Nature 364, 249-252 [CrossRef][Medline] [Order article via Infotrieve]
  49. Thomas, D., Patterson, S. D., and Bradshaw, R. A. (1995) J. Biol. Chem. 270, 28924-28931 [Abstract/Free Full Text]
  50. Prekeris, R., Mayhew, M. W., Cooper, J. B., and Terrian, D. M. (1996) J. Cell Biol. 132, 77-90 [Abstract]
  51. Misra-Press, A., Rim, C. S., Yao, H., Roberson, M. S., and Stork, P. J. S. (1995) J. Biol. Chem. 270, 14587-14596 [Abstract/Free Full Text]
  52. Kwak, S. P., and Dixon, J. E. (1995) J. Biol. Chem. 270, 1156-1160 [Abstract/Free Full Text]
  53. Wu, J., Lau, L. F., and Sturgill, T. W. (1994) FEBS Lett. 353, 9-12 [CrossRef][Medline] [Order article via Infotrieve]
  54. Alessi, D. R., Gomez, N., Moorhead, G., Lewis, T., Keyse, S. M., and Cohen, P. (1995) Curr. Biol. 5, 283-295 [Medline] [Order article via Infotrieve]
  55. Porfiri, E., and McCormick, F. (1996) J. Biol. Chem. 271, 5871-5877 [Abstract/Free Full Text]
  56. Rozakis-Adcock, M., van der Geer, P., Mbamalu, G., and Pawson, T. (1995) Oncogene 11, 1417-1426 [Medline] [Order article via Infotrieve]
  57. Waters, S. B., Holt, K. H., Ross, S. E., Syu, L.-J., Guan, K.-L., Saltiel, A. R., Koretzky, G. A., and Pessin, J. E. (1995) J. Biol. Chem. 270, 20883-20886 [Abstract/Free Full Text]
  58. Brunet, A., Pagès, G., and Pouysségur, J. (1994) FEBS Lett. 346, 299-303 [CrossRef][Medline] [Order article via Infotrieve]
  59. Mancillas, J. R., Siggins, G. R., and Bloom, F. E. (1986) Science 231, 161-163 [Medline] [Order article via Infotrieve]
  60. Goodman, C. S., and Shatz, C. J. (1993) Neuron 72, 77-98
  61. Cadete-Leite, A., Tavares, M. A., Uylings, H. B. M., and Paula-Barbosa, M. (1988) Brain Res. 473, 1-14 [CrossRef][Medline] [Order article via Infotrieve]
  62. Tavares, M. A., Paula-Barbosa, M. M., and Volk, B. (1986) J. Submicrosc. Cytol. 18, 725-730 [Medline] [Order article via Infotrieve]
  63. Volk, B. (1984) in Neurobehavioral Teratology (Yanai, J., ed), pp. 163-193, Elsevier, Amsterdam
  64. Pentney, R. J., and Quackenbush, L. J. (1990) Alcohol. Clin. Exp. Res. 14, 878-886 [Medline] [Order article via Infotrieve]
  65. West, J. R., Hodges, C. A., and Black, A. C. J. (1981) Science 211, 957-959 [Medline] [Order article via Infotrieve]
  66. McNamara, J. O. (1994) J. Neurosci. 14, 3413-3425 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.